Cancer immunotherapies have changed the landscape of cancer treatment during the past
few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Skin cancer is the most commonly diagnosed cancer worldwide. Understanding the natural
history of skin cancer will provide a framework for the creation of prevention and control …

Abstract Background Immune checkpoint inhibitors (ICIs) may induce persistent immune-
related adverse events (irAEs). We investigated persistent irAEs and implications on …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target inhibitory
molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell …

Background Immune checkpoint inhibitor (ICI)–mediated psoriasis poses significant
diagnostic and therapeutic challenges. Objective To report data on ICI-mediated psoriasis …

An individual may be considered a cancer survivor from diagnosis through the balance of
their life. 1 In contrast to those with early-stage cancer, survivorship care for people with …

Checkpoint inhibitor (CPI) therapy has vastly improved long‐term outcomes in metastatic
malignant melanoma (MMM). Therapy takes the form of monoclonal antibody infusions that …

Antibody-mediated blockade of co-inhibitory molecules such as cytotoxic T lymphocyte-
associated protein 4, PD1 and PDL1 elicits potent antitumor responses and improves the …

Abstract Background Immune checkpoint inhibitors (ICIs) have become a central part of
cancer care. However, the survivorship outcomes in patients treated with ICIs are …